Milestone Pharmaceuticals Shares Plunge After Q1 CARDAMYST Revenue Misses Forecast
Milestone Pharmaceuticals saw its shares plunge after first-quarter CARDAMYST revenue fell short of analysts’ consensus expectations. The disappointing product performance raises concerns about the company’s growth outlook and will likely pressure near-term valuations.
1. Revenue Shortfall Triggers Stock Decline
Milestone Pharmaceuticals’ CARDAMYST generated lower-than-expected first-quarter revenue, falling beneath the consensus forecast. The revenue shortfall prompted a steep sell-off in the company’s shares, reflecting investor concerns over its near-term growth trajectory and potential valuation headwinds.
Related News
PYPL
PayPal Expands PYUSD Stablecoin to 70 Markets for Instant Global Payments
PYPL•
SMCZ
SMCZ Inverse ETF Plunges 18.5% to $13.10 on Semiconductor Strength
SMCZ•
NVDA
Nvidia Raises July Quarter Guidance, Forecasts $91B Fiscal 2027 Revenue
NVDA•
KDP
Keurig Dr Pepper Sets $0.23 Dividend, CEO to Present at June 3 Conference
KDP•
IPW
iPower Cuts Q3 Costs 66%, Narrows Loss to $0.3M, Secures $2.6M Sublease
IPW•
Sources
F